Scarica l'app Stockscreener
97.39
1.54%
-1.5083
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$98.90
Aprire:
$97.25
Volume 24 ore:
5.60M
Relative Volume:
0.63
Capitalizzazione di mercato:
$123.23B
Reddito:
$28.73B
Utile/perdita netta:
$5.97B
Rapporto P/E:
20.50
EPS:
4.75
Flusso di cassa netto:
$10.37B
1 W Prestazione:
-5.69%
1M Prestazione:
-5.63%
6M Prestazione:
+0.84%
1 anno Prestazione:
+50.00%
Intervallo 1D:
$95.30
$97.58
Intervallo di 1 settimana:
$95.30
$105.17
Portata 52W:
$62.07
$119.96
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Confronta GILD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
97.37 | 123.23B | 28.73B | 5.97B | 10.37B | 4.75 |
|
LLY
Lilly Eli Co
|
748.88 | 697.63B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
156.42 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
185.06 | 345.13B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
65.29 | 294.98B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.19 | 224.15B | 53.22B | 12.86B | 14.85B | 6.39 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Drugmaker Gilead pledges $11 billion investment in U.S. manufacturing - The Business Journals
Gilead Sciences Increases Investment in U.S. Operations - Contract Pharma
Earth Day Focus for Gilead SciencesEvery Action Has an Impact - ACCESS Newswire
Gilead ups its US investment plans by $11 billion - Pharmaphorum
Gilead Pumps $11B More Into US Manufacturing, Hopes To Add 3,000 Jobs - BioSpace
Gilead tees up $11B in new US manufacturing, R&D investments - Fierce Pharma
Gilead to invest $32 billion in US manufacturing and R&D - The Pharma Letter
How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock - Yahoo Finance
Gilead announces $11 billion in new investments in US - MSN
Gilead is latest to pledge allegiance to America with $32B manufacturing commitment - FirstWord Pharma
Gilead boosts planned US investments by $11 billion amid tariff threat - MSN
Gilead (GILD) to Boost U.S. Operations with $11 Billion Investment | GILD Stock News - GuruFocus
Gilead Sciences (GILD) Boosts U.S. Investment by $11 Billion - GuruFocus
Gilead Sciences Announces $11 Billion U.S. Investment BoostNews and Statistics - IndexBox
Gilead to invest $32B in U.S.through 2030 (GILD:NASDAQ) - Seeking Alpha
Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing By Investing.com - Investing.com
Gilead announces $11 billion in new investments in US By Reuters - Investing.com
Gilead Sciences (GILD) U.S. Investment to Create $43B in Value to U.S. Economy - StreetInsider
Gilead Boosts Planned US Investments by $11 Billion Amid Tariff Threat - US News Money
Gilead To Invest $32 Bln In U.S. Manufacturing And R&D Through 2030 - marketscreener.com
Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025 - simplywall.st
Fighting the World’s Most Devastating Diseases Is the Focus of This Installment of “The Centrifuge Sessions - CSRwire
Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025 - BioSpace
Gilead (GILD): Livdelzi Shows Promising Results for PBC Treatment | GILD Stock News - GuruFocus
GILD: Promising Results from Gilead's Bulevirtide Study for Chronic Hepatitis Delta | GILD Stock News - GuruFocus
Gilead to Invest $11 Billion to Bolster Domestic Operations - WSJ
Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy - GuruFocus
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment - Business Wire
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Gilead (GILD) Sees Bearish Options Activity with Heavy Put Trading | GILD Stock News - GuruFocus
Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions" - marketscreener.com
Gilead: Sure, Why Not, But Not The CDRs (GILD:CA) - Seeking Alpha
What Are Wall Street Analysts' Target Price for Gilead Sciences Stock? - Nasdaq
Mizuho Adjusts Price Target on Gilead Sciences to $117 From $100, Maintains Outperform Rating - marketscreener.com
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term - Yahoo
What Are Wall Street Analysts' Target Price For Gilead Sciences Stock? - Barchart.com
Gilead (GILD) Sees 24% Stock Surge Amid Tariff Resilience - GuruFocus
Gilead and Vertex Pharma named among biotech’s tariff safe havens - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
Here's What to Expect From Gilead Sciences’ Next Earnings Report - MSN
Struggling Peninsula biotech with Gilead lineage is latest purchase for activist investor - The Business Journals
Gilead Sciences (GILD): A Promising Pick Amid Economic Uncertain - GuruFocus
June 13th Options Now Available For Gilead Sciences (GILD) - Nasdaq
Gilead Agrees To Pay $202M To Settle Alleged Speaker Kickback Claims In FCA Suit - Law360
Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors - MSN
Gilead Sciences' (NASDAQ:GILD) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Gilead Sciences Stock Falls as Slumping COVID-19, Cancer Drug Sales Hit Revenue - MSN
BlackRock, Inc. Reduces Stake in Gilead Sciences Inc. - GuruFocus
Gilead Sciences: Hold Rating Maintained Amid Near-Term Challenges and Limited Growth Prospects - TipRanks
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now? - Yahoo Finance
Gilead Will Pay $202M In DOJ Deal Over Drug Kickbacks - Law360
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):